Recent Updates
Recently added Catalysts
BFRI

Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022

Key Takeaway: WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31,
Price reaction · baseline $66.6 (2022-03-31 close) · hit after-hours · 2 other BFRI headline(s) in the window, move may be shared
day 0 close
+5.4%
day 1 · peak
+9.3%
day 3
+6.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
14.8%
average across 3 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
BF-200 ALA 1%
Phase 2 · Actinic Keratosis

Full Press Release Details

WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
Event: Biofrontera Inc. Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call
Date: Friday, April 8, 2022
Time : 11:00 a.m. Eastern time
Conference call : 1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast: Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com .
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com.
Last updated: Apr 1, 2022